← All stocks

Travere Therapeutics, Inc.

TVTX Mostly scheduled

CIK 0001438533 #1223 in the set updated 22 Sep 2026

Bought (1 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (1 mo)

$66.38M

$0.00 on a plan · $66.34M straight out of an exercise

Sold at will

$42.61K

1 of 41 sales

Net

−$66.38M

−$42.61K against sales at will

By person

16 insiders · 41 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Dube Eric M

CHIEF EXECUTIVE OFFICER

—

$25.39M (8) scheduled

−$25.39M

432,886

0.4592%

$28.12M

+19.6%

Heerma Peter

EVP, CHIEF COMMERCIAL OFFICER

—

$17.86M (7) scheduled

−$17.86M

117,066

0.1242%

$7.60M

+7.1%

ROTE WILLIAM E.

Chief Research Officer

—

$13.14M (6) scheduled

−$13.14M

98,197

0.1042%

$6.38M

+12.8%

Cline Christopher R.

CHIEF FINANCIAL OFFICER

—

$3.19M (5) scheduled

−$3.19M

87,508

0.0928%

$5.68M

+17.3%

Inrig Jula

EVP, Head of R&D & CMO

—

$2.79M (4) scheduled

−$2.79M

100,491

0.1066%

$6.53M

+62.2%

REED ELIZABETH E

Chief Legal Officer and GC

—

$2.34M (4) scheduled

−$2.34M

105,389

0.1118%

$6.85M

+31.2%

Meckler Jeffrey A

Director

—

$1.35M (4) scheduled

−$1.35M

91,500

0.0971%

$5.94M

+13.0%

Calvin Sandra

SVP, CHIEF ACCOUNTING OFFICER

—

$335.00K (3) scheduled

−$335.00K

42,353

0.0449%

$2.75M

−18.6%

LYONS GARY A

Director

—

61,500

0.0652%

$3.99M

+20.6%

Coughlin Timothy

Director

—

56,250

0.0597%

$3.65M

+14.8%

Baynes Roy D.

Director

—

41,500

0.0440%

$2.70M

+33.9%

Squarer Ron

Director

—

39,375

0.0418%

$2.56M

+36.4%

Orwin John A

Director

—

39,375

0.0418%

$2.56M

+36.4%

Poole Sandra

Director

—

34,000

0.0361%

$2.21M

+44.7%

Bruhn Suzanne Louise

Director

—

32,750

0.0347%

$2.13M

+47.2%

Williams Brinkley Ruth

Director

—

29,750

0.0316%

$1.93M

+54.5%

Individual transactions

Insider

Date

Role

Action

Price

Amount

Cline Christopher R.

2 Sep 2026

CHIEF FINANCIAL OFFICER

Sell

642

$66.37

$42.61K

Show all 41 transactions →

What was left out

Form 4 filings counted 9

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 40

Sales at will 1

Transactions with no price 0

Shares from compensation/vesting 964,959

History held since 2 Sep 2016